Stacy MS - Invivyd Chief Officer

IVVD Stock  USD 0.59  0.08  11.94%   

Executive

Stacy MS is Chief Officer of Invivyd
Age 55
Address 1601 Trapelo Road, Waltham, MA, United States, 02451
Phone781 819 0080
Webhttps://invivyd.com

Invivyd Management Efficiency

The company has return on total asset (ROA) of (0.5356) % which means that it has lost $0.5356 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9656) %, meaning that it created substantial loss on money invested by shareholders. Invivyd's management efficiency ratios could be used to measure how well Invivyd manages its routine affairs as well as how well it operates its assets and liabilities. As of November 27, 2024, Return On Tangible Assets is expected to decline to -0.91. In addition to that, Return On Capital Employed is expected to decline to -1.22. At present, Invivyd's Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Debt To Assets is expected to grow to 0.01, whereas Non Current Assets Total are forecasted to decline to about 3.8 M.
Invivyd currently holds 2.17 M in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. Invivyd has a current ratio of 8.96, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Invivyd's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

Dawn JonesIntel
N/A
Felix PohThe Coca Cola
N/A
Hani AbouhalkaJohnson Johnson
N/A
John PitzerIntel
N/A
Brett IversenMicrosoft
N/A
Takeshi NumotoMicrosoft
53
Szymon RomikIntel
N/A
Christine PambianchiIntel
56
Robin LeopoldJPMorgan Chase Co
56
Manuel PrietoThe Coca Cola
57
Harvey AndersonHP Inc
49
Anton UlmerJPMorgan Chase Co
N/A
Mary FrancisChevron Corp
60
Chandrakant PatelHP Inc
N/A
Alice TakhtajanJPMorgan Chase Co
N/A
Michael BodnerJohnson Johnson
N/A
Judson AlthoffMicrosoft
51
Nicole GilesJPMorgan Chase Co
44
Matt PoirierIntel
N/A
Yafit CohnThe Travelers Companies
N/A
Ashna ZaheerThe Coca Cola
N/A
Invivyd, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. Invivyd, Inc. was incorporated in 2020 and is based in Waltham, Massachusetts. Invivyd operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 101 people. Invivyd (IVVD) is traded on NASDAQ Exchange in USA. It is located in 1601 Trapelo Road, Waltham, MA, United States, 02451 and employs 94 people. Invivyd is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Invivyd Leadership Team

Elected by the shareholders, the Invivyd's board of directors comprises two types of representatives: Invivyd inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Invivyd. The board's role is to monitor Invivyd's management team and ensure that shareholders' interests are well served. Invivyd's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Invivyd's outside directors are responsible for providing unbiased perspectives on the board's policies.
Laura Walker, CoFounder Officer
Elham PharmD, Chief Officer
Peter MD, Chief Officer
Robert Allen, Chief Officer
Jill JD, Chief Secretary
Mark Wingertzahn, Senior Affairs
Timothy Lee, Chief Officer
Jeremy Gowler, Chief Officer
Kyra Faircloth, Advocacy Affairs
Frederick Driscoll, Principal CFO
Rebecca Dabora, Chief Officer
MD MS, Chief Officer
Stacy MS, Chief Officer
Julie MBA, Senior Resources
MBA Duke, Chief Officer
David MBA, CEO Director
Heidi MS, VP CEO
MSc MD, Chief Officer
Scott Young, Senior Communications

Invivyd Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Invivyd a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Invivyd is a strong investment it is important to analyze Invivyd's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Invivyd's future performance. For an informed investment choice regarding Invivyd Stock, refer to the following important reports:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Invivyd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
For information on how to trade Invivyd Stock refer to our How to Trade Invivyd Stock guide.
You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Invivyd. If investors know Invivyd will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Invivyd listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.95)
Revenue Per Share
0.02
Return On Assets
(0.54)
Return On Equity
(0.97)
The market value of Invivyd is measured differently than its book value, which is the value of Invivyd that is recorded on the company's balance sheet. Investors also form their own opinion of Invivyd's value that differs from its market value or its book value, called intrinsic value, which is Invivyd's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Invivyd's market value can be influenced by many factors that don't directly affect Invivyd's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Invivyd's value and its price as these two are different measures arrived at by different means. Investors typically determine if Invivyd is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Invivyd's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.